Infectious complications after gastrointestinal surgery in patients with ovarian carcinoma and malignant ascites.
One hundred four patients with ovarian cancer underwent intestinal reconstruction as part of a cytoreductive effort or for relief of intestinal obstruction from July 1980 to June 1990. Twenty-four percent of patients were obstructed preoperatively, while the remaining seventy-six percent had bowel resections performed in concert with a debulking procedure. The overall infectious complication rate was 14.4%. No statistical association was found between the presence of ascites at the time of laparotomy and infectious morbidity (P = 0.58). The use of a preoperative mechanical bowel preparation was associated with a significant reduction in infectious morbidity (P = 0.01). Additionally, patients considered in adequate nutritional condition experienced significantly less infectious complications than those patients in poor nutritional condition (P = 0.03). Intestinal procedures involving the large bowel were marginally associated with increased infectious complications (P = 0.13). Neither preoperative radiotherapy, the presence of preoperative obstruction, disease presence, extent of debulking, number of intestinal procedures, or hand versus stapled anastomosis was found to be significantly associated with infectious complications. It is concluded that the presence of ascites does not increase the infectious complication rate in ovarian cancer patients who undergo small or large bowel reconstructive procedures. Additionally, patients with preoperative bowel obstruction or previous abdominal radiation therapy were not found to experience a significant increase in the infectious complication rate in the current series.
Donato
D
D
Department of Obstetrics and Gynecology, University of Miami School of Medicine, Florida 33101.
Angelides
A
A
Irani
H
H
Penalver
M
M
Averette
H
H
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001201:Ascites / Q000473:pathology; D001424:Bacterial Infections / Q000209:etiology / Q000517:prevention & control; D002951:Citrates / Q000627:therapeutic use; D019343:Citric Acid; D003141:Communicable Diseases / Q000453:epidemiology / Q000209:etiology*; D004733:Enema; D005260:Female; D006801:Humans; D007415:Intestinal Obstruction / Q000209:etiology / Q000601:surgery*; D008875:Middle Aged; D009017:Morbidity; D010051:Ovarian Neoplasms / Q000473:pathology / Q000601:surgery*; D011183:Postoperative Complications / Q000382:microbiology*; D012189:Retrospective Studies
D000900:Anti-Bacterial Agents; D002951:Citrates; D019343:Citric Acid